Mitchell & Pahl Private Wealth LLC Raises Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Mitchell & Pahl Private Wealth LLC boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 4.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,489 shares of the company’s stock after purchasing an additional 1,761 shares during the period. Mitchell & Pahl Private Wealth LLC’s holdings in Elanco Animal Health were worth $478,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health during the 4th quarter valued at $29,000. NBC Securities Inc. bought a new position in Elanco Animal Health during the first quarter worth about $40,000. Parallel Advisors LLC increased its stake in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after purchasing an additional 1,852 shares in the last quarter. Versant Capital Management Inc raised its position in shares of Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock valued at $46,000 after purchasing an additional 1,740 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after buying an additional 2,059 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares of the company’s stock, valued at $1,136,881.80. The trade was a 9.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.89% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ELAN has been the topic of a number of analyst reports. Piper Sandler lowered their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Morgan Stanley reduced their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Stifel Nicolaus upped their price target on Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, May 19th. Finally, UBS Group lowered their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $13.46 on Monday. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of 33.65, a PEG ratio of 2.50 and a beta of 1.49. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The business has a 50-day simple moving average of $10.60 and a 200 day simple moving average of $11.39. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.34 earnings per share. On average, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.